---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-025324"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-06-16T10:30:49+00:00"
generated_at: "2026-06-16T10:35:20.730152+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics stockholders elect directors, approve executive pay, auditor, and Series B conversion

## Summary
- Class II directors David M. Epstein, Ph.D. and Dan Weng, M.D. re-elected with ~70.2M and ~70.5M votes for, respectively.
- Non-binding advisory vote on executive compensation approved with 70.5M votes for, 34,907 against.
- Ratification of Grant Thornton Zhitong as independent auditor for FY2026 approved with 72.5M votes for.
- Approval of conversion of Series B Convertible Preferred Stock into common stock passed with 70.5M votes for.
- Broker non-votes reported for all proposals except auditor ratification (none).

## SEC filing metadata
- accession: 0001140361-26-025324
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-06-16T10:30:49+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/ef20076059_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-025324
- JSON: https://secwatch.observer/filing/0001140361-26-025324.json
- Plain text: https://secwatch.observer/filing/0001140361-26-025324.txt

## Key facts
- Shareholder Votes
  GYRE THERAPEUTICS, INC. shareholders approved Non-Binding Advisory Vote on Executive Compensation at the 2026-06-10 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: Proposal 2: Non-Binding Advisory Vote on Executive Compensation The compensation of the Company’s named executive officers was approved, on a non-binding, advisory basis, as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,478,374 34,907 1,160 1,985,197
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm
- Shareholder Votes
  GYRE THERAPEUTICS, INC. shareholders approved Election of Class II Directors at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: The following Class II director nominees were elected to serve until the 2029 Annual Meeting of Stockholders based upon the following votes: Nominee Votes For Votes Withheld Broker Non-Votes • David M. Epstein, Ph.D. 70,160,332 354,109 1,985,197 • Dan Weng, M.D. 70,483,425 31,016 1,985,197
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm
- Shareholder Votes
  GYRE THERAPEUTICS, INC. shareholders approved Ratification of Independent Auditor at the 2026-06-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: Proposal 3: Ratification of Independent Auditor The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows: Votes For Votes Against Abstentions Broker Non-Votes 72,487,596 11,626 416 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm
- Shareholder Votes
  GYRE THERAPEUTICS, INC. shareholders approved Approval of Conversion of Series B Preferred Stock at the 2026-06-10 meeting.
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: Proposal 4: Approval of Conversion of Series B Preferred Stock The issuance of shares of the Company’s common stock, par value $0.001 per share, upon conversion of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share, was approved, in accordance with Nasdaq Listing Rule 5635(a), as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,497,125 16,031 1,285 1,985,197
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/0001140361-26-025324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.